Skip to main content

Patient-Centered Care or Drug-Centered Care: The Influence of Pharmaceutical Marketing on Medical Science and Public Health

  • Chapter
  • First Online:
Philosophical Issues in Pharmaceutics

Part of the book series: Philosophy and Medicine ((PHME,volume 122))

Abstract

Medical leaders today call increasingly for patient-centered care, which is often contrasted with doctor-centered care and disease-centered care. One threat to patient-centered care which does not easily fit into these categories, however, is what one might label drug-centered care. Drug-centered “care” arises when pharmaceutical industry marketing exerts a deleterious influence over both the medical profession and the general public. This influence is easy to detect when it assumes blatant forms such as financial incentives to overprescribe but is harder to perceive when it takes the form of changing the way we think about disease and indeed about human life. Two case studies that illustrate this deleterious influence are antidepressant drugs and drugs for type 2 diabetes. The inverse benefit law explains why these forms of pharmaceutical marketing constitute a threat to the public’s health.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Angell, M. 2004. The Truth about the Drug Companies: How They Deceive Us and What to Do about It. New York: Random House.

    Google Scholar 

  • Applbaum, K. 2009. Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster. Culture, Medicine and Psychiatry 33: 185–215.

    Article  Google Scholar 

  • ———. 2010. Shadow Science: Zyprexa, Eli Lilly, and the Globalization of Pharmaceutical Damage Control. BioSocieties 5: 236–255.

    Article  Google Scholar 

  • Avorn, J. 2004. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf.

    Google Scholar 

  • Boussageon, R., T. Bejan-Angoulvant, M. Saadatian-Elahi, et al. 2011. Effect Of Intensive Glucose Lowering Treatment On All Cause Mortality, Cardiovascular Death, And Microvascular Events In Type 2 Diabetes: Meta-Analysis Of Randomised Controlled Trials. British Medical Journal 343: d4169.

    Article  Google Scholar 

  • Braun, S.R. 2013. Promoting “Low T”—A Medical Writer’s Perspective. Journal of American Medical Association Internal Medicine 173: 1458–1460.

    Google Scholar 

  • Brody, H. 2007. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Lanham: Rowman and Littlefield.

    Google Scholar 

  • Brody, H., and D.W. Light. 2011. The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health. American Journal of Public Health 101: 399–404.

    Article  Google Scholar 

  • Dolan P.L. 2013. Physician EHRs Emerge as Hot Advertising Venue for Drugs. American Medical News. http://www.amednews.com/article/20130121/business/130129987/4/. Accessed 12 Sep 2014.

  • Duggan, P.S., G. Geller, L.A. Cooper, and M.C. Beach. 2006. The Moral Nature of Patient-Centeredness: Is It “Just the Right Thing to Do”? Patient Education and Counseling 62: 271–276.

    Article  Google Scholar 

  • Farmer, A.J., R. Perera, A. Ward, et al. 2012. Meta-analysis of Individual Patient Data In Randomised Trials Of Self Monitoring Of Blood Glucose In Patients With Non-Insulin Treated Type 2 Diabetes. British Medical Journal 344: e486.

    Article  Google Scholar 

  • Friedman, R.A. 2012. Grief, Depression, and the DSM-V. The New England Journal of Medicine 366: 1855–1857.

    Article  Google Scholar 

  • Gagnon, M.A., and J. Lexchin. 2008. The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. PLoS Medicine 5(1): e1.

    Article  Google Scholar 

  • Gerstein, H.C., S. Yusuf, J. Bosch, et al. 2006. Effect of Rosiglitazone on the Frequency of Diabetes in Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomised Controlled Trial. Lancet 368: 1096–1105.

    Article  Google Scholar 

  • Gøtzsche, P.C. 2013. Deadly Medicines and Organized Crime: How Big Pharma Has Corrupted Healthcare. London: Radcliffe Medical Press.

    Google Scholar 

  • Greene, J.A. 2008. Prescribing by Numbers: Drugs and the Definition of Disease. Baltimore: Johns Hopkins University Press.

    Google Scholar 

  • Healy, D. 1997. The Antidepressant Era. Cambridge, MA: Harvard University Press.

    Google Scholar 

  • ———. 2003. Let Them Eat Prozac. Toronto: James Lorimer.

    Google Scholar 

  • Kassirer, J.P. 2005. On the Take: How Medicine’s Complicity with Big Business Can Endanger Your Health. New York: Oxford University Press.

    Book  Google Scholar 

  • Kishore, P., S.H. Kim, and J.P. Crandall. 2012. Glycemic Control and Cardiovascular Disease: What’s a Doctor to Do? Current Diabetes Reports 12: 255–264.

    Article  Google Scholar 

  • Leo, J., and J. Lacasse. 2008. The Media and The Chemical Imbalance Theory of Depression. Society 45: 35–45.

    Article  Google Scholar 

  • Light, D.H., ed. 2012. The Risks of Prescription Drugs. New York: Columbia University Press.

    Google Scholar 

  • Montori, V.M., and M. Fernandez-Balsells. 2009. Glycemic Control in Type 2 Diabetes: Time for an Evidence-based About-face? Annals of Internal Medicine 150: 803–808.

    Article  Google Scholar 

  • Moynihan, R. 2010. Rosiglitazone, Marketing, and Medical Science. British Medical Journal 340: c1848.

    Article  Google Scholar 

  • Moynihan, R., and A. Cassels. 2006. Selling Sickness: How the World’s Biggest Pharmaceutical Companies are Turning Us All into Patients. New York: Nation.

    Google Scholar 

  • Nissen, S.E., and K. Wolski. 2007. Effect of Rosiglitazone on the Risk Of Myocardial Infarction and Death from Cardiovascular Causes. The New England Journal of Medicine 356: 2457–2471.

    Article  Google Scholar 

  • Noble, P. 2013. FDA Eases Restriction to Avandia Access. Thomson Reuters/Life Science Connect. https://lsconnect.thomsonreuters.com/fda-eases-restrictions-avandia-access/. Accessed 13 Sept 2014.

  • Psaty, B.M., and D. Rennie. 2003. Stopping Drug Research to Save Money: A Broken Pact with Researchers and Patients. Journal of the American Medical Association 289: 2128–2131.

    Google Scholar 

  • Reinhardt, U.E. 2001. Perspectives on the Pharmaceutical Industry. Health Affairs (Millwood) 20: 136–149.

    Article  Google Scholar 

  • Tanne, J.H. 2009. American Psychiatric Association Says No to Industry Funding for Symposiums. British Medical Journal 338: b1426.

    Article  Google Scholar 

  • Tiefer, L. 2006. Female Sexual Dysfunction: A Case Study of Disease Mongering and Activist Resistance. PLoS Medicine 3(4): e178.

    Article  Google Scholar 

  • Torrey, E.F. 2002. The Going Rate on Shrinks: Big Pharma and the Buying of Psychiatry. The American Prospect 13: 15–16.

    Google Scholar 

  • Turner, E.H., A.M. Matthews, E. Linardatos, et al. 2008. Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. The New England Journal of Medicine 358: 252–260.

    Article  Google Scholar 

  • UK Prospective Diabetes Study Group. 2008. Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Events in Type 2 Diabetes: UKPDS 38. British Medical Journal 317: 703–713.

    Article  Google Scholar 

  • Washington, A.E., and S.H. Lipstein. 2011. The Patient-Centered Outcomes Research Institute—Promoting Better Information, Decisions, and Health. The New England Journal of Medicine 365: e31.

    Google Scholar 

  • Whitaker, R. 2010. Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America. New York: Crown.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Howard Brody .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Brody, H. (2017). Patient-Centered Care or Drug-Centered Care: The Influence of Pharmaceutical Marketing on Medical Science and Public Health. In: Ho, D. (eds) Philosophical Issues in Pharmaceutics. Philosophy and Medicine, vol 122. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-0979-6_7

Download citation

Publish with us

Policies and ethics